Determine the Pharmacokinetics and Safety of Brivanib in Chinese Subjects With Advanced Primary Liver Cancer (Hepatocellular Carcinoma: HCC)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

November 30, 2013

Study Completion Date

November 30, 2013

Conditions

Hepatocellular Carcinoma

Interventions

DRUG

Brivanib

Tablets, Oral, 800 mg, Once daily, Until withdrawal of consent, disease progression or until unmanageable toxicity

Trial Locations (3)

Local Institution, Beijing

Local Institution, Harbin

Local Institution, Nanjing